These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9239836)

  • 1. Tumor necrosis factor-alpha production and disease severity after immunization with enriched major core protein (p26) and/or infection with equine infectious anemia virus.
    Costa LR; Santos IK; Issel CJ; Montelaro RC
    Vet Immunol Immunopathol; 1997 Jun; 57(1-2):33-47. PubMed ID: 9239836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antibody-dependent enhancement assays are insensitive indicators of in vivo vaccine enhancement of equine infectious anemia virus.
    Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Jul; 259(2):416-27. PubMed ID: 10388665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An attenuated EIAV vaccine strain induces significantly different immune responses from its pathogenic parental strain although with similar in vivo replication pattern.
    Lin YZ; Shen RX; Zhu ZY; Deng XL; Cao XZ; Wang XF; Ma J; Jiang CG; Zhao LP; Lv XL; Shao YM; Zhou JH
    Antiviral Res; 2011 Nov; 92(2):292-304. PubMed ID: 21893100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus.
    Hammond SA; Raabe ML; Issel CJ; Montelaro RC
    Virology; 1999 Sep; 262(2):416-30. PubMed ID: 10502520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus.
    Issel CJ; Horohov DW; Lea DF; Adams WV; Hagius SD; McManus JM; Allison AC; Montelaro RC
    J Virol; 1992 Jun; 66(6):3398-408. PubMed ID: 1316455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between the induction of Th1 cytokines by an attenuated equine infectious anemia virus vaccine and protection against disease progression.
    Zhang X; Wang Y; Liang H; Wei L; Xiang W; Shen R; Shao Y
    J Gen Virol; 2007 Mar; 88(Pt 3):998-1004. PubMed ID: 17325374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.
    Hammond SA; Li F; McKeon BM; Cook SJ; Issel CJ; Montelaro RC
    J Virol; 2000 Jul; 74(13):5968-81. PubMed ID: 10846078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement.
    Raabe ML; Issel CJ; Cook SJ; Cook RF; Woodson B; Montelaro RC
    Virology; 1998 May; 245(1):151-62. PubMed ID: 9614876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equine infectious anemia virus (EIAV) humoral responses of recipient ponies and antigenic variation during persistent infection.
    Rwambo PM; Issel CJ; Adams WV; Hussain KA; Miller M; Montelaro RC
    Arch Virol; 1990; 111(3-4):199-212. PubMed ID: 2162160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient suppression of equine immune responses by equine infectious anemia virus (EIAV).
    Newman MJ; Issel CJ; Truax RE; Powell MD; Horohov DW; Montelaro RC
    Virology; 1991 Sep; 184(1):55-66. PubMed ID: 1651604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.
    Li F; Craigo JK; Howe L; Steckbeck JD; Cook S; Issel C; Montelaro RC
    J Virol; 2003 Jul; 77(13):7244-53. PubMed ID: 12805423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus.
    Hammond SA; Cook SJ; Falo LD; Issel CJ; Montelaro RC
    Virology; 1999 Feb; 254(1):37-49. PubMed ID: 9927572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of an equine infectious anemia virus Env-pseudotyped reporter virus.
    Tallmadge RL; Brindley MA; Salmans J; Mealey RH; Maury W; Carpenter S
    Clin Vaccine Immunol; 2008 Jul; 15(7):1138-40. PubMed ID: 18448619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?
    Leroux C; Cadoré JL; Montelaro RC
    Vet Res; 2004; 35(4):485-512. PubMed ID: 15236678
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological method using recombinant S2 protein to differentiate equine infectious anemia virus (EIAV)-infected and EIAV-vaccinated horses.
    Jin S; Issel CJ; Montelaro RC
    Clin Diagn Lab Immunol; 2004 Nov; 11(6):1120-9. PubMed ID: 15539516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.
    Craigo JK; Li F; Steckbeck JD; Durkin S; Howe L; Cook SJ; Issel C; Montelaro RC
    J Virol; 2005 Mar; 79(5):2666-77. PubMed ID: 15708986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of equine infectious anemia virus core proteins produced in a baculovirus expression system to serological diagnosis.
    Kong XG; Pang H; Sugiura T; Sentsui H; Onodera T; Matsumoto Y; Akashi H
    Microbiol Immunol; 1997; 41(12):975-80. PubMed ID: 9492183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of the correlation between the plasma viral load and protective immunity induced by the equine infectious anemia attenuated vaccine and its parental virulent strain].
    Cao XZ; Lin YZ; Li L; Jiang CG; Zhao LP; Lv XL; Zhou JH
    Bing Du Xue Bao; 2010 Mar; 26(2):128-33. PubMed ID: 20480642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long terminal repeats are not the sole determinants of virulence for equine infectious anemia virus.
    Tu YB; Zhou T; Yuan XF; Qiu HJ; Xue F; Sun CQ; Wang L; Wu DL; Peng JM; Kong XG; Tong GZ
    Arch Virol; 2007 Jan; 152(1):209-18. PubMed ID: 16932982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies and PMBC from EIAV infected carrier horses recognize gp45 and p26 synthetic peptides.
    Soutullo A; García MI; Bailat A; Racca A; Tonarelli G; Malan Borel I
    Vet Immunol Immunopathol; 2005 Dec; 108(3-4):335-43. PubMed ID: 16105689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.